Genebiotech Co Stock Working Capital
| 086060 Stock | KRW 3,415 65.00 1.94% |
GeneBioTech Co fundamentals help investors to digest information that contributes to GeneBioTech's financial success or failures. It also enables traders to predict the movement of GeneBioTech Stock. The fundamental analysis module provides a way to measure GeneBioTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GeneBioTech stock.
GeneBioTech |
GeneBioTech Co Company Working Capital Analysis
GeneBioTech's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current GeneBioTech Working Capital | 16.42 B |
Most of GeneBioTech's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GeneBioTech Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, GeneBioTech Co has a Working Capital of 16.42 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The working capital for all Republic of Korea stocks is notably lower than that of the firm.
GeneBioTech Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GeneBioTech's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GeneBioTech could also be used in its relative valuation, which is a method of valuing GeneBioTech by comparing valuation metrics of similar companies.GeneBioTech is currently under evaluation in working capital category among its peers.
GeneBioTech Fundamentals
| Return On Equity | 0.72 | |||
| Return On Asset | -0.0149 | |||
| Profit Margin | (0.07) % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 41.48 B | |||
| Shares Outstanding | 8.37 M | |||
| Shares Owned By Insiders | 29.77 % | |||
| Shares Owned By Institutions | 0.56 % | |||
| Price To Earning | 19.69 X | |||
| Price To Sales | 0.63 X | |||
| Revenue | 62.81 B | |||
| Gross Profit | 9.43 B | |||
| EBITDA | (24.38 M) | |||
| Net Income | (484.4 M) | |||
| Cash And Equivalents | 7.43 B | |||
| Total Debt | 2.15 B | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 4.62 X | |||
| Book Value Per Share | 3,523 X | |||
| Cash Flow From Operations | (2.84 B) | |||
| Number Of Employees | 37 | |||
| Beta | 0.88 | |||
| Market Capitalization | 35.37 B | |||
| Total Asset | 60.37 B | |||
| Retained Earnings | 12.5 B | |||
| Working Capital | 16.42 B | |||
| Current Asset | 27.77 B | |||
| Current Liabilities | 11.35 B | |||
| Z Score | 10.6 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 60.37 B |
About GeneBioTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GeneBioTech Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneBioTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneBioTech Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with GeneBioTech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GeneBioTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneBioTech will appreciate offsetting losses from the drop in the long position's value.Moving together with GeneBioTech Stock
The ability to find closely correlated positions to GeneBioTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneBioTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneBioTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneBioTech Co to buy it.
The correlation of GeneBioTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GeneBioTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GeneBioTech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GeneBioTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in GeneBioTech Stock
GeneBioTech financial ratios help investors to determine whether GeneBioTech Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GeneBioTech with respect to the benefits of owning GeneBioTech security.